Alzheimer’s disease: Clinical trials and drug development

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744

Network pharmacology: the next paradigm in drug discovery

Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622

Alzheimer’s disease

Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria

Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685

Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis

Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275

Memantine in Moderate-to-Severe Alzheimer's Disease

Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043

Cholinesterase inhibitors for Alzheimer's disease

Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906

Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892

Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers

Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560

Hipótese amiloide e o tratamento da doença de Alzheimer: revisão dos estudos clínicos realizados.

Delanogare, E., Flores, D., de Souza, R. M., Souza, L. D., & Moreira, E. L. G. (2019) · VITTALLE - Revista de Ciências da Saúde · doi:10.14295/vittalle.v31i1.8395 · Cited by 6

Pathways in the Drug Development for Alzheimer’s Disease (1906-2016): A Bibliometric Study

Schilder, I. P. A., Veening-Griffioen, D. H., Ferreira, G. S., van Meer, P. J. K., Wied, C. C. G., Schellekens, H., Boon, W., & Moors, E. H. M. (2020) · Journal of Scientometric Research · doi:10.5530/jscires.9.3.35 · Cited by 5

Kinematic body sensor networks and behaviourmetrics for objective efficacy measurements in neurodegenerative disease drug trials

Gavriel, C., Thomik, A. A. C., Lourencco, P. R., Nageshwaran, S., Athanasopoulos, S., Sylaidi, A., Festenstein, R., & Faisal, A. A. (2015) · Wearable and Implantable Body Sensor Networks · doi:10.1109/bsn.2015.7299426 · Cited by 5

Optimal population screening policies for Alzheimer’s disease*

Onen-Dumlu, Z., Sayın, S., & Gürvit, I. H. (2018) · IISE Transactions on Healthcare Systems Engineering · doi:10.1080/24725579.2018.1543738 · Cited by 5

Emerging Therapeutic Strategies in Alzheimer's Disease

Chiba, T. (2013) · InTech eBooks · doi:10.5772/55293 · Cited by 5

PET Applications in Animal Models of Neurodegenerative and Neuroinflammatory Disorders

Higuchi, M., Maeda, J., Ji, B., Tokunaga, M., Zhang, M., Maruyama, M., Ono, M., Fukumura, T., & Suhara, T. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_167 · Cited by 5

Uncovering the Molecular Mechanism of Actions between Pharmaceuticals and Proteins on the AD Network

Cao, S., Yu, L., Mao, J., Wang, Q., & Ruan, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144387 · Cited by 5

Amyloid Chemical Probes and Theranostics: Steps Toward Personalized Medicine in Neurodegenerative Diseases

Bolognesi, M. L. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677252.ch09 · Cited by 5

ARIA from off-key operas?

Frisoni, G. B. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70021-2 · Cited by 5

The role of lifestyle factors in primary prevention of dementia

Deckers (2017) · Research Publications (Maastricht University) · doi:10.26481/dis.20170511kd · Cited by 6

Nichtinvasive Stimulationsverfahren in der Neurologie

Antonenko, D., & Flöel, A. (2016) · Der Nervenarzt · doi:10.1007/s00115-016-0115-z · Cited by 6

Dynamic decision making simulation with limited data via causal inference

Sun, J., Wang, Y., Zhang, H., & Zhu, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-28623-0 · Cited by 4

Protective effects and mechanism of Paecilomyces cicadae TJJ1213 intracellular polysaccharide against H2O2 ‐induced PC12 cells damage

Tian, J., Xu, Q., Wang, X., Zhang, X., Chen, X., Rui, X., Zhang, Q., Dong, M., & Li, W. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14253 · Cited by 4

Repurposing pharmaceuticals for Alzheimer's treatment via adjusting the lactoferrin interacting proteins

Liu, X., Cui, J., Luan, C., Li, Y., Tong, X., Jiang, Y., Wang, Z.-J., & Guo, C. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144230 · Cited by 4

Functional near-infrared spectroscopy and vagus somatosensory evoked potentials add to the power of established parameters such as poor cognitive performance, dsyosmia and APOe genotype to predict cognitive decline over 8 years in the elderly

Herrmann, M. J., Wuttke, A., Breuninger, L., Eff, J., Ettlinger, S., Fischer, M., Götzelmann, A., Gram, A., Pomper, L. D., Schneider, E., et al. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02859-y · Cited by 4

Co‐activation of Selective Nicotinic Acetylcholine Receptor Subtypes Is Required for Neuroprotection against Alzheimer's Disease

Lee, R., Kim, G., Black, E. R., & Kim, S. (2026) · Advanced Science · doi:10.1002/advs.77858 · Cited by 4

Conformationally restrained carbamoylcholine homologues. Synthesis, pharmacology at neuronal nicotinic acetylcholine receptors and biostructural considerations

Revenga, M. D. L. F., Balle, T., Jensen, A. A., & Frølund, B. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.029 · Cited by 4

beta-Amyloid: Enemy or Remedy?

Hohlfeld, R., & Wekerle, H. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004586 · Cited by 4

Memantine: A Treatment for Alzheimer’s Disease with a New Formulation

Makino, K. M., & Porsteinsson, A. P. (2011) · Aging Health · doi:10.2217/ahe.11.31 · Cited by 4

Are Inflammatory Profiles the Key to Personalized Alzheimer's treatment?

Brothers, H. M., & Wilcock, D. M. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.40 · Cited by 3

Cellular Transplantation as the Treatment of Alzheimer’s Diseas e in Mouse Models

Suzuki, N., & Shimizu, J. (2016) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000219 · Cited by 4

Histological and Behavioral Phenotypes of a Novel Mutated APP Knock-In Mouse

Plucińska, K., Crouch, B., Yeap, J., Stoppelkamp, S., Riedel, G., & Platt, B. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180336 · Cited by 4

Bexarotene cannot reduce amyloid beta plaques through inhibition of production of amyloid beta peptides: in silico and in vitro study

Huy, P. D. Q., Thai, N. Q., Bednáriková, Z., Linh, H. Q., Gažová, Z., & Li, M. S. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c8cp00049b · Cited by 4

Practicality of promoting brain health and early dementia screening in elderly residents with friendly mobile App: Beijing plan

Zhang, Z., Jiang, M., Zhang, J., He, L., Li, X., Chen, Y., Lü, P., Wei, D., Guan, Q., Wang, J., et al. (2020) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2019-0535 · Cited by 3

Systematic Search for a Predictor for the Clinical Observables of Alzheimer’s Disease

Das, A. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c06725 · Cited by 4

Leveraging molecular quantitative trait loci to comprehend complex diseases/traits from the omics perspective

Zhu, Z., Chen, X., Zhang, S., Yu, R., Qi, C., Cheng, L., & Zhang, X. (2023) · Human Genetics · doi:10.1007/s00439-023-02602-9 · Cited by 5

LPC20K modified from krill oil ameliorates the scopolamine-induced cognitive impairment

Park, K., Kong, C. H., Kang, W. C., Jeon, M., Lee, W. H., Lee, J., Kim, S. C., Jung, S. Y., & Ryu, J. H. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114836 · Cited by 4

Antidepressant sertraline increases thioflavin-S and Congo red deposition in APPswe/PSEN1dE9 transgenic mice

Liao, M.-H., Lin, Y., Gau, F.-Y., Tseng, C., Wu, D.-C., Hsu, C.-Y., Chung, K., Li, R., Hu, C., Then, C. K., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1260838 · Cited by 4

Combinatorial therapy in Alzheimer's disease

Giri, M. A., Kendre, P. N., Bhalke, R. D., Pande, V. V., Autade, K. A., & Sumbe, R. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00026-1 · Cited by 4

Assay Suitability for Natural Product Screening: Searching for Leads to Fight Alzheimerʼs Disease

Vasänge, M. (2014) · Planta Medica · doi:10.1055/s-0034-1383063 · Cited by 4

Dementia: beyond multi-morbidity

Iliffe, S., & Manthorpe, J. (2017) · Journal of Public Mental Health · doi:10.1108/jpmh-05-2017-0019 · Cited by 4

Translational research on disease‐modifying therapies for neurodegenerative diseases

Katsuno, M., Watanabe, H., Tanaka, F., & Sobue, G. (2013) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.7 · Cited by 4

HSV1 in Alzheimer’s disease: Myth or reality?

Špeljko, T., Jutrić, D., & Šimić, G. (2011) · Translational Neuroscience · doi:10.2478/s13380-011-0009-2 · Cited by 4

A Knowledge-based Integrative Modeling Approach for In-Silico Identification of Mechanistic Targets in Neurodegeneration with Focus on Alzheimer's Disease

Younesi, E. (2014) · Cited by 4

NGF and BDNF Gene Therapy for Alzheimer’s Disease

Tuszynski, M. H., & Nagahara, A. H. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_3 · Cited by 4

Immunotherapeutic and pharmacological approaches for the treatment of Alzheimer’s disease

Moraes, M. U., & Gaudet, T. J. (2018) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzy001 · Cited by 7

Effects of δ-Catenin on APP by Its Interaction with Presenilin-1.

Dai, W., Ryu, T., Kim, H., Jin, Y. H., Cho, Y.-C., & Kim, K. (2019) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0273 · Cited by 4

Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

Wang, W. T., Tailor, B. A., Cohen, D. S., & Huang, X. (2019) · PubMed · Cited by 4

Molecular Mechanisms Involved in the Neuroprotective Action of Phytochemicals

Sunkaria, A., Yadav, A., Sharma, S. K., & Sandhir, R. (2017) · Wiley eBooks · doi:10.1002/9781119155195.ch27 · Cited by 4

Color Dependence of OLED Phototherapy for Cognitive Function and Beta-Amyloid Reduction through ADAM17 and BACE1

Noh, B., Lee, H.-J., Lee, J., Lee, J., Joo, B., Jung, Y., Park, M., Kang, S., Oh, S., Hwang, J.-W., et al. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01162 · Cited by 3

Creatine and Taurine as Novel Competitive Inhibitors of Acetylcholinesterase: A Biochemical Basis for Nutritional Modulation of Brain Function

Adamski, P., Szeleszczuk, Ł., Gackowski, M., & Grodner, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311309 · Cited by 3

Replacement of the bryostatin A- and B-pyran rings with phenyl rings leads to loss of high affinity binding with PKC

Petersen, M. E., Kedei, N., Lewin, N. E., Blumberg, P. M., & Keck, G. E. (2016) · Tetrahedron Letters · doi:10.1016/j.tetlet.2016.09.040 · Cited by 3

Flavonoid-Based Derivatives for Modulating Various Targets of Alzheimer’s Disease

Pandey, J. (2023) · Springer eBooks · doi:10.1007/978-981-99-6038-5_11 · Cited by 3

A Bibliometric Analysis of Global Research Trends in Elderly Population Diseases

Wu, H., & Zhao, Z. (2025) · Public Health Nursing · doi:10.1111/phn.13557 · Cited by 3

3-Hydroxybutyrate, a metabolite in sustaining neuronal cell vitality: a mendelian randomization and in vitro experimentation

Hu, X., Lin, Y. W., Huang, K., Xu, H., Fu, C. H., Ou, J., Fan, X., Li, Z., Fang, J., & Fang, S. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00960-x · Cited by 3

Alzheimer’s Disease Drug Discovery may be Misled by Wrong Animal Models

Nazem, A. (2014) · Journal of Gerontology & Geriatric Research · doi:10.4172/2167-7182.1000e127 · Cited by 3

Alzheimers sykdom og genetikk

Rongve, A., Årsland, D., & Graff, C. (2013) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.12.0873 · Cited by 3

A Mechanism for the Inhibition of Tau Neurotoxicity: Studies with Artificial Membranes, Isolated Mitochondria, and Intact Cells

Naveh‐Tassa, S., Ben-Zichri, S., Lacham‐Hartman, S., Oren, O., Slobodnik, Z., Eremenko, E., Toiber, D., Jelinek, R., & Papo, N. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00045 · Cited by 4

Intratarget Microdosing for Deep Phenotyping of Multiple Drug Effects in the Live Brain

Kim, J. S., Ahn, S. W., Deans, K., Thompson, D., Ferland, B., Divakar, P., Dominas, C. A., & Jonas, O. H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.855755 · Cited by 3

Toward the optimized assessment of clinical outcomes in studies of novel treatments for Alzheimer’s disease

Lipton, R. B., Podger, L., Stewart, W. F., Gómez‐Ulloa, D., Rodriguez, W., Runken, M. C., Barnes, F. B., & Serrano, D. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2149324 · Cited by 3

Lecanemab (Leqembi): an amyloid beta monoclonal antibody approved for the treatment of Alzheimer’s disease

Sang, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23932-8.00035-2 · Cited by 3

Alzheimer’s Disease: Epidemiology, Etiology, Risk Factors, and Future Predictions

Jojo, G. M., Johnson, J., Kuppusamy, G., & Karri, V. V. S. R. (2024) · Springer eBooks · doi:10.1007/978-981-96-0259-9_3 · Cited by 3

Discovery, Biological Evaluation and Binding Mode Investigation of Novel Butyrylcholinesterase Inhibitors Through Hybrid Virtual Screening

Li, L., Zhao, P., Yang, C., Yin, Q., Wang, N., Liu, Y., & Li, Y. (2025) · Molecules · doi:10.3390/molecules30102093 · Cited by 3

Neuroprotective and Antiaging Essential Oils and Lipids in Plants

Das, M., & Devi, K. P. (2019) · Reference series in phytochemistry · doi:10.1007/978-3-319-78030-6_89 · Cited by 3

Alzheimer's disease: new therapies and the role of biomarkers.

Dudash, K. (2011) · PubMed Central · Cited by 3

The chalcone derivative Chana 1 protects against amyloid�β peptide-induced oxidative stress and cognitive impairment

Lee, Y.-H. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.984 · Cited by 3

Should interventions to treat or prevent Alzheimer’s disease be tested in a population or as targeted treatment of highly selected study participants?

Ousset, P., Delrieu, J., & Vellas, B. J. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt228 · Cited by 3

Neuroprotective effect of bisabolangelone on hydrogen peroxide-induced neurotoxicity in SH-SY5Y cells

Wang, J., Yan, X.-M., Li, Z., Luo, H., Huang, N., & Deng, W. (2015) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1421-x · Cited by 3

Current Trends in Memory Implantation and Rehabilitation

Jang, H. J., Park, S. W., & Kwag, J. (2015) · Trends in augmentation of human performance · doi:10.1007/978-94-017-7239-6_5 · Cited by 3

Modern Concepts of Alzheimer,s Disease Pathogenesis: Novel Approaches to Pharmacotherapy (Review)

Komleva, Y., Kuvacheva, N. V., Lopatina, O., Gorina, Y., Frolova, O., Teplyashina, E., Petrova, M., & Salmina, A. (2015) · Современные технологии в медицине · doi:10.17691/stm2015.7.3.19 · Cited by 2

Neuroregeneration: Disease Modeling and Therapeutic Strategies for Alzheimer’s and Parkinson’s Diseases

Santiago-Lopez, A. J., Hovell, C. M., Lee, H., & Kim, Y. (2015) · Biosystems & biorobotics · doi:10.1007/978-3-319-21813-7_13 · Cited by 3

The BRICHOS Domain

Presto, J., & Johansson, J. (2015) · Springer briefs in molecular science · doi:10.1007/978-3-319-16564-6_1 · Cited by 3

Diabetes Associated Memory Impairment: Perspective on Management Strategies

Sharma, G., Sonu, & Harikumar, S. (2015) · International journal of pharma research and review · Cited by 3

Effects of Bioactive Components of Green Tea on Alzheimer's Disease

Ide, K., Kawasaki, Y., Kawakami, K., & Yamada, H. (2018) · Studies in natural products chemistry · doi:10.1016/b978-0-444-64058-1.00005-4 · Cited by 3

Overview of Cannabis including Kampo Medicine and Therapy for Treatment of Dementia: A Review

Wenger, T., Watanabe, K., Sasaki, Y., Kanazawa, K., Shimizu, K., Sirikantaramas, S., Shoyama, Y., Taura, F., Morimoto, S., & Shoyama, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.713228 · Cited by 3

The impact of homocysteine and B vitamins on Alzheimer’s disease, cognitive performance and structural brain changes

Hooshmand, B. (2013) · Figshare · Cited by 3

Discovery and Targeted Monitoring of Biomarkers Using Liquid Chromatography, Ion Mobility Spectrometry , and Mass Spectrometry

Adams, K. J. (2018) · doi:10.25148/etd.fidc006592 · Cited by 3

Economic Evaluation of Interventions for Screening of Dementia

Saha, S., Gerdtham, U., Toresson, H., Minthon, L., & Jarl, J. (2018) · Lund University Publications (Lund University) · Cited by 3

The role of vitamins in dementia prevention and cognitive health: A comprehensive review

Ahmed, A., Khan, H., Shah, S. S. U. D., Kiyani, M. M., Al‐Hussain, F., Bashir, S., Fu, X., & Li, P. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251379700 · Cited by 2

Neuritin: a multifaceted neuroprotective factor with emerging applications for neurodegeneration

Mongan, K. L., & Sharma, T. P. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1698598 · Cited by 2

Brain Extracellular Space: From an Overlooked Dimension to Catalyst of a Novel Neuroscience Paradigm

Han, H., Dai, H., Lopes, L. S., Ni, R., Combes, B. F., Song, Y., Tan, H., Xu, M., Li, H., Lv, S., et al. (2026) · Cyborg and Bionic Systems · doi:10.34133/cbsystems.0529 · Cited by 2

A novel nasal mucosal peptide-modified co-delivery system for ginsenoside Rg1, Rb1, and notoginseng saponin R1 in the amelioration of AD

Li, Y., Hu, C., Xia, C., Wang, X., Zhou, X., Xu, R., Li, Y., Mo, F., Zhao, B., Xu, L., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04532-w · Cited by 2

A rapid and sensitive HPLC–MS/MS method for determination of an aminopyridazine derived anti-neuroinflammatory agent (ZW14) in dog plasma: Application to a pharmacokinetic study

Deng, J., Liu, P., Lv, B., Guo, J., Liang, F., Tang, J., & Xie, H. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.03.042 · Cited by 2

Exploring anti-acetylcholinesterase, antioxidant and metal chelating activities of extracts of Moringa oleifera L. for possible prevention and cure of Alzheimers disease

Rasheed, A., Ghous, T., Kh., A. Y., Nasim, F., FehmidaYounas, & Andleeb, S. (2014) · Scientific Research and Essays · doi:10.5897/sre2013.5537 · Cited by 2

Challenges in Dementia Studies

Ong, K. T. (2018) · InTech eBooks · doi:10.5772/intechopen.72866 · Cited by 2

Demenzen

Lautenschlager, M. M., Lautenschlager, N. T., & Förstl, H. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_66 · Cited by 2

Metal-Organic Framework Based Drug Delivery for Alzheimer's Therapy and Clinical Progress

Bukhari, S. N. A. (2022) · Mini-Reviews in Organic Chemistry · doi:10.2174/1570193x19666220316142832 · Cited by 2

Nanomedical drug delivery for neurodegenerative disease

Kaur, N., Kumar, V., Mahender, T., Maji, I., Mahajan, S., Aalhate, M., Singh, P. K., & Sahu, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00016-2 · Cited by 2

Osteoporosis is associated with elevated baseline cerebrospinal fluid biomarkers and accelerated brain structural atrophy among older people

Pan, H., Cao, J., Wu, C., Huang, F., Wu, P., Lang, J., & Liu, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.958050 · Cited by 2

GRK5 Deficiency in the Hippocampus Leads to Cognitive Impairment via Abnormal Microglial Alterations

Shen, H., Zhang, T., Ji, Y., Zhang, Y., Wang, Y., Jiang, Y., Chen, X., Liang, Q., Wu, K., Lu, X., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03151-4 · Cited by 2

Alzheimer's disease and green coffee bean extract

Younis, N. N., & Eissa, R. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90052-2.00040-8 · Cited by 2

Innovative Discoveries in Neurosurgical Treatment of Neurodegenerative Diseases: A Narrative Review

Findlay, M. C., Khan, M., Kundu, M., Johansen, C. M., & Lucke-Wold, B. P. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230911125646 · Cited by 2

Effects of extracts and manna of Echinops cephalotes on impaired cognitive function induced by scopolamine in mice

Sadeghi, G., Dinani, M. S., & Rabbani, M. (2024) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_27_23 · Cited by 2

Overview and Applications of Nanocarrier-Based Drug Delivery for Alleviating Alzheimer’s Disease

Khan, S. A., Haider, M. F., & Naseem, N. (2025) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0042 · Cited by 2

Association between genetically proxied PPARG activation and early onset Alzheimer's disease: A drug target Mendelian randomization study

Zhang, L., Wu, Y., Jin, Q., & Wang, C. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251359579 · Cited by 2

A comprehensive strategy for dementia from primary prevention to end‐stage management

Arai, H. (2011) · Psychogeriatrics · doi:10.1111/j.1479-8301.2011.00379.x · Cited by 2

Alzheimer’s Dementia and Lifestyle: Towards a Primary Prevention

Walach, H., & Loef, M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6852-3_12 · Cited by 2

Biomarker utility in Alzheimer's disease clinical trials

Soares, H. D., & Lovestone, S. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2013.09.002 · Cited by 2

γ-secretase inhibitors for treating Alzheimer’s disease: rationale and clinical data

Panza, F., Frisardi, V., Imbimbo, B. P., Seripa, D., Solfrizzi, V., & Pilotto, A. (2011) · Clinical Investigation · doi:10.4155/cli.11.86 · Cited by 2

L’imagerie TEP-traceurs des plaques amyloïdes : le point de vue du clinicien

Delrieu, J., & Vellas, B. J. (2011) · Médecine Nucléaire · doi:10.1016/j.mednuc.2011.08.004 · Cited by 4

The Contribution of the Amyloid Hypothesis to the Understanding of Alzheimer's Disease: A Critical Overview

Morelli, L., Perry, G. L., & Tagliavini, F. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/709613 · Cited by 2

Single administration of a novel γ-secretase modulator ameliorates cognitive dysfunction in aged C57BL/6J mice

Hayama, T., Murakami, K., Watanabe, T., Maeda, R., Kamata, M., & Kondo, S. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.020 · Cited by 2

Part 1: Notch-sparing γ-secretase inhibitors: The identification of novel naphthyl and benzofuranyl amide analogs

Lu, D., Wei, H., Zhang, J., Gu, Y., Osenkowski, P., Ye, W., Selkoe, D. J., Wolfe, M. S., & Augelli‐Szafran, C. E. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.040 · Cited by 2

2. Dementia

Moritoyo, T. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.1916 · Cited by 2

Proteopathies: Biological, Molecular and Clinical Perspectives

Chowhan, R. K., Dar, T. A., & Singh, L. R. (2015) · Springer eBooks · doi:10.1007/978-81-322-2467-9_8 · Cited by 2

Noninfectious Disease Vaccines

El-Turabi, A., & Bachmann, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00040-7 · Cited by 2

Radiofluorination process development and Tau protein imaging studies of [F-18]FEONM

Hsu, J., Chen, J.-T., Lin, S.-H., Chu, K.-Y., Tu, Y.-H., Chang, K., Huang, L.-Y., Huang, Y.-C., Farn, S., Hsu, S., et al. (2016) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2016.09.035 · Cited by 2

Research of new drugs for Alzheimer's disease

Hroudová, J. (2017) · Psychiatrie pro praxi · doi:10.36290/psy.2017.002 · Cited by 2

The Limbic System

ten Donkelaar, H. J. (2011) · Springer eBooks · doi:10.1007/978-3-642-19134-3_14 · Cited by 2

Recent Advances in Approved, Withdrawn, Experimental and Investigational Drugs in Clinical Trials for Alzheimer’s disease

Deshpande, R. (2022) · Medicinal & Analytical Chemistry International · doi:10.23880/macij-16000174 · Cited by 1

Drug development status for Alzheimer’s disease: present scenario

Misra, S., & Medhi, B. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1316-x · Cited by 31

Alzheimer's Disease: A Review

Poonam Dapke* Ms. Sonali Kalam, D. G. S. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.10130202

Current therapeutics for Alzheimer’s disease and clinical trials

Xiao, D., & Zhang, C. (2024) · Exploration of Neuroscience · doi:10.37349/en.2024.00048 · Cited by 30

In search of Alzheimer’s disease treatment methods: trends of clinical trials

Pakulaite-Kazliene, G., Regelskytė, V., Audronytė, E., Kuzmickienė, J., & Kaubrys, G. (2018) · Neurologijos seminarai · doi:10.29014/ns.2018.03 · Cited by 1

The Development of Pharmacological Therapies for Alzheimer’s Disease

Ping, L., Sun, J., Cheng, Q., Yang, Y., Cordato, D. J., & Gao, J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00282-z · Cited by 16